SMAR1 Forms a Ternary Complex with p53-MDM2 and Negatively Regulates p53-mediated Transcription

Journal of Molecular Biology

Volumn 388, Issue 4, 2009, Pages 691-702

  Pavithra, Lakshminarasimhan ^a   Mukherjee, Srijata ^b   Sreenath, Kadreppa ^a   Kar, Sanchari ^b   Sakaguchi, Kazuyasu ^c   Roy, Siddhartha ^b   Chattopadhyay, Samit ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

damage recovery; MDM2; p53; SMAR1; ternary complex

Indexed keywords

HISTONE DEACETYLASE 1; MATRIX ATTACHMENT REGION BINDING PROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN SMAR1; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; COMPLEX FORMATION; CONTROLLED STUDY; DEACETYLATION; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; MATRIX ATTACHMENT REGION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

EID: 67349267742     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.03.033     Document Type: Article

References (37)

1. Oren M., Damalas A., Gottlieb T., Michael D., Taplick J., Leal J.F., et al. Regulation of p53: intricate loops and delicate balances. Biochem. Pharmacol. 64 (2002) 865-871
2. Hupp T.R., Meek D.W., Midgley C.A., and Lane D.P. Regulation of the specific DNA binding function of p53. Cell 71 (1992) 875-886
3. Rui Y., Xu Z., Lin S., Li Q., Rui H., Luo W., et al. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J. 23 (2004) 4583-4594
4. Takenaka I., Morin F., Seizinger B.R., and Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem. 270 (1995) 5405-5411
5. Honda R., and Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19 (2000) 1473-1476
6. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., and Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275 (2000) 8945-8951
7. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., and Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 91 (1994) 2230-2234
8. Yew P.R., Liu X., and Berk A.J. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8 (1994) 190-202
9. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 69 (1992) 1237-1245
10. Minsky N., and Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol. Cell 16 (2004) 631-639
11. Freedman D.A., and Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol 18 (1998) 7288-7293
12. Hsieh J.K., Chan F.S., O'Connor D.J., Mittnacht S., Zhong S., and Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3 (1999) 181-193
13. Thut C.J., Goodrich J.A., and Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11 (1997) 1974-1986
14. Kobet E., Zeng X., Zhu Y., Keller D., and Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl Acad. Sci. USA 97 (2000) 12547-12552
15. Joseph T.W., Zaika A., and Moll U.M. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J. 17 (2003) 1622-1630
16. Shirangi T.R., Zaika A., and Moll U.M. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J. 16 (2002) 420-422
17. Rampalli S., Pavithra L., Bhatt A., Kundu T.K., and Chattopadhyay S. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol. Cell Biol. 25 (2005) 8415-8429
18. Singh K., Mogare D., Giridharagopalan R.O., Gogiraju R., Pande G., and Chattopadhyay S. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion. PLoS. ONE 2 (2007) e660
19. Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., and Chattopadhyay S. Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. J. Biol. Chem. 280 (2005) 16019-16029
20. Jalota-Badhwar A., Kaul-Ghanekar R., Mogare D., Boppana R., Paknikar K.M., and Chattopadhyay S. SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53. J. Biol. Chem. 282 (2007) 9902-9913
21. Kaul R., Mukherjee S., Ahmed F., Bhat M.K., Chhipa R., Galande S., and Chattopadhyay S. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. Int. J. Cancer 103 (2003) 606-615
22. Kar S., Sakaguchi K., Shimohigashi Y., Samaddar S., Banerjee R., Basu G., et al. Effect of phosphorylation on the structure and fold of transactivation domain of p53. J. Biol. Chem. 277 (2002) 15579-15585
23. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., and Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (1996) 948-953
24. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
25. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., et al. p53 is regulated by the lysine demethylase LSD1. Nature 449 (2007) 105-108
26. Vousden K.H., and Lane D.P. p53 in health and disease. Nature Rev. Mol. Cell Biol. 8 (2007) 275-283
27. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315
28. Feng L., Lin T., Uranishi H., Gu W., and Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell Biol. 25 (2005) 5389-5395
29. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 280 (2005) 26776-26787
30. Ohkubo S., Tanaka T., Taya Y., Kitazato K., and Prives C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J. Biol. Chem. 281 (2006) 16943-16950
31. Zhao L.Y., Liu J., Sidhu G.S., Niu Y., Liu Y., Wang R., and Liao D. Negative regulation of p53 functions by Daxx and the involvement of MDM2. J. Biol. Chem. 279 (2004) 50566-50579
32. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
33. Gu W., Shi X.L., and Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 387 (1997) 819-823
34. Carter S., Bischof O., Dejean A., and Vousden K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biol. 9 (2007) 428-435
35. Tang Y., Zhao W., Chen Y., Zhao Y., and Gu W. Acetylation is indispensable for p53 activation. Cell 133 (2008) 612-626
36. Joseph T.W., and Moll U.M. Analysis of nuclear and cytoplasmic degradation of p53 in cells after stress. Methods Mol. Biol. 234 (2003) 211-217
37. Henderson B.R., and Eleftheriou A. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp. Cell Res. 256 (2000) 213-224